Debiopharm Group
Debiopharm Group is a Swiss biopharmaceutical company that in-licenses early-stage oncology and infectious disease compounds, develops them through clinical stages using proprietary sustained-release and ADC platforms, and out-licenses them to global pharma partners such as Ipsen, Takeda, and Merck KGaA for commercialization.
- Company typePrivate
- Founded1979
- HeadquartersLausanne, Switzerland
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Debiopharm Group does
Debiopharm Group is an independent, family-controlled Swiss biopharmaceutical company founded in 1979 and headquartered in Lausanne, operating through three integrated divisions: drug development (Debiopharm International), GMP drug manufacturing (Debiopharm Research & Manufacturing, FDA-inspected facility in Martigny), and a strategic digital health investment arm (Debiopharm Innovation Fund, approximately USD 100 million deployed since 2008 across ~14 portfolio companies). The core business model is in-licensing of early-stage compounds from universities and biotech startups, internal development through clinical stages using proprietary technology platforms, and out-licensing to global pharmaceutical partners — including Ipsen, Takeda, Merck KGaA, Ferring, Yakult, and ITM — for worldwide commercialization in exchange for milestone payments and royalties. The firm has produced two historically blockbuster therapies (oxaliplatin/Eloxatin and triptorelin/Decapeptyl) and currently maintains approximately 15 active R&D programs.
The proprietary technology base centers on three platform families. DEBIO SPHERES is a world-leading PLGA-based injectable sustained-release technology powering marketed 1/3/6-month triptorelin formulations and the in-development 12-month formulation Debio 4326. The MultiLINK platform offers a modular suite of tunable, peptide-based, cathepsin B-cleavable ADC linkers supporting high DAR (up to DAR 16) and dual-payload delivery via MLINK Duo (DAR 8+8). AbYlink is a non-enzymatic, site-specific antibody conjugation technology attaching payloads or imaging agents to the Fc region of any IgG in under one hour under GMP-compatible conditions. The clinical pipeline spans oncology (lunresertib/PKMYT1 and zedoresertib/WEE1 inhibitors with FDA Fast Track Designation; multiple ADC candidates including Debio 1562M for AML/MDS; Debio 0532 for HER3-positive solid tumors; Debio 2512 bispecific ADC), endocrinology (Debio 4126 quarterly octreotide for acromegaly in Phase III), and infectious disease (Debio 1453, a first-in-class FabI inhibitor for Neisseria gonorrhoeae developed in partnership with GARDP for global access). The firm operates at approximately 420 employees under the parent holding company Après-demain SA, with the Mauvernay family maintaining ownership and Thierry Mauvernay serving as President alongside CEO Bertrand Ducrey.
Commercially, Debiopharm monetizes through milestone payments and royalties from out-licensed products, contract manufacturing services from its FDA-inspected facility, and equity-driven returns from the Innovation Fund's digital health portfolio (notable historical exits include Kaiku Health to Elekta in 2020 and Voluntis to AptarGroup in 2021). The strategic posture emphasizes platform reusability — PLGA sustained-release, ADC conjugation, and linker chemistry are applied across multiple programs — and selective AI integration through external partnerships (Genialis for biomarker discovery, Risklick for protocol authoring, NetTargets for ADC target identification, ViewsML for virtual biomarker staining from pathology). Geographic reach spans Europe, North America, and selected LATAM and APAC markets for clinical operations, with global commercialization executed exclusively through licensing partners rather than direct sales infrastructure.
Debiopharm Group firmographics
Firmographics- Name
- Debiopharm Group
- Legal name
- Debiopharm International SA
- Website
- http://www.debiopharm.com/
- Company type
- Private
- Founded year
- 1979
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Debiopharm Group is a Swiss biopharmaceutical company that in-licenses early-stage oncology and infectious disease compounds, develops them through clinical stages using proprietary sustained-release and ADC platforms, and out-licenses them to global pharma partners such as Ipsen, Takeda, and Merck KGaA for commercialization.
- Ownership category
- akta.pro rank
Debiopharm Group industry classification
Industry- Product category
- Biopharmaceutical Drug Development
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Debiopharm Group is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices4 records
Markets served
Debiopharm Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
Revenue model
- Drug Development and Out-Licensing: Debiopharm in-licenses innovative compounds from universities or start-ups, develops them through clinical stages, and out-licenses to pharmaceutical partners for worldwide commercialization. Revenue generated through milestone payments and royalties from commercialization partners.
- Drug Manufacturing: Debiopharm Research & Manufacturing operates as a pharmaceutical research, development and production facility, inspected and registered with main regulatory authorities, providing manufacturing services.
- Digital Health Investment: Debiopharm Innovation Fund invests in digital health and smart data start-ups, providing strategic funding and gaining equity stakes in portfolio companies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Debiopharm Group product offering
Product offeringCore offering
Debiopharm in-licenses early-stage biologics and small-molecule compounds from universities and start-ups, develops them through preclinical and clinical stages using proprietary drug delivery platforms (PLGA-based DEBIO SPHERES sustained-release, MultiLINK ADC linkers, AbYlink antibody conjugation), and out-licenses to global pharmaceutical partners for commercialization. The group operates an FDA-inspected drug manufacturing facility in Martigny and a digital health investment fund backing AI/data start-ups.
Product overview
Debiopharm Group operates as an independent biopharmaceutical company with three divisions: drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing), and digital health investment (Debiopharm Innovation Fund). Its core product offerings span proprietary drug delivery technology platforms and a clinical-stage pipeline of targeted oncology and infectious disease therapies. The drug delivery portfolio is anchored by the DEBIO SPHERES™ PLGA-based sustained-release platform (used in marketed products Decapeptyl®/Pamorelin® and clinical candidates Debio 4126 and Debio 4326), the AbYlink™ antibody conjugation technology, and the MultiLINK™ ADC Technology Suite (including MLINK Duo for dual-payload delivery). The clinical pipeline includes CD37 ADCs (Debio 1562M in Phase I/II for AML/MDS, Debio 1562), HER3/HER2 ADCs (Debio 0532, Debio 2512), DDR inhibitors (lunresertib/PKMYT1 and zedoresertib/WEE1, Fast Track Designated 2026), and antibiotics (Debio 1453 in Phase I for gonorrhea). The Innovation Fund invests in digital health/AI startups including Genialis (AI biomarker discovery), ViewsML (virtual biomarker staining), and Risklick (protocol AI). Debiopharm in-licenses early-stage compounds, develops them through clinical stages, and out-licenses to global pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Brands
- AbYlink: Proprietary antibody conjugation technology platform developed by Debiopharm for developing antibody-drug conjugates (ADCs).
- MultiLINK
Products and services
- Decapeptyl / Pamorelin (Triptorelin)
Quantifiable outcome
- Two blockbuster therapies developed and commercialized worldwide (oxaliplatin, triptorelin with combined sales exceeding $1.8 billion in 2004)
Companies that use Debiopharm Group
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Debiopharm Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Debiopharm Group partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and strategic.
- GARDP (Global Antibiotic Research and Development Partnership)coreCollaboration and license agreement to pursue development of Debio 1453, a novel first-in-class antibiotic targeting Neisseria gonorrhoeae. GARDP leads non-clinical and clinical development activities and CMC, while Debiopharm completes Phase I trial. GARDP granted manufacturing and commercialization rights in 160+ countries for global access.
- GenialisstrategicDebiopharm deploying Genialis software to support AI-driven biomarker discovery, leveraging AI and data management technologies for precision medicine development.
- ITM Isotope Technologies Munich SEstrategicCollaboration on Phase 1/2 trial evaluating ITM-94 as diagnostic agent for clear cell renal cell carcinoma. ITM and Debiopharm announced first patient imaged in new study arm.
- NetTargetscoreStrategic research collaboration to develop next-generation dual-payload ADCs for drug-resistant cancers. Combines NetTargets' AI discovery platform with Debiopharm's MLINK Duo technology for synergistic drug combinations and coordinated delivery of two distinct warheads.
- RisklickstrategicPilot collaboration using Risklick's Protocol AI software for clinical trial protocol development. Successful proof-of-concept completed to generate robust clinical protocols within structured environment.
- Alkyon TherapeuticsstrategicResearch collaboration to advance next-generation radioligand therapies, combining expertise in radiochemistry and drug delivery technologies.
- Oncodesign ServicesstrategicStrategic collaboration to advance radiopharmaceuticals in preclinical research, combining Oncodesign's specialized expertise with Debiopharm's radiopharmaceutical development capabilities.
- Genome & CompanycoreLicensing deal for novel target ADC (now Debio 0633) targeting IND filing by late 2027-2028. Part of strategic shift from microbiome-focused biotech to first-in-class oncology drug developer.
- SunRock BiopharmacoreExtended licensing agreement to develop HER3-EGFR bispecific ADCs (Debio 2512). Debiopharm licensed SunRock's anti-HER3/HER2 antibody to explore full potential of bispecific ADC development.
- IpsencoreLong-term commercialization partnership for Decapeptyl (triptorelin), one of Ipsen's leading marketed products. Major pharmaceutical partnership established over decades.
- TakedacoreRecent long-term commercialization partnership with Takeda for pharmaceutical products.
- Merck KGaAcoreLong-term commercialization partnership with Merck KGaA for pharmaceutical products.
- FerringcoreLong-term commercialization partnership with Ferring Pharmaceuticals.
- YakultcoreLong-term commercialization partnership with Yakult for pharmaceutical products.
- ITMcoreLong-term commercialization partnership with ITM for pharmaceutical products, including recent radiopharmaceutical collaboration.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Debiopharm Group competitors and assessment
Company assessmentDirect peers
- Recordati: Italian specialty pharma with established brands in urology, endocrinology, and rare diseases, plus active in-licensing partnerships. Comparable to Debiopharm in mid-size specialty focus, reliance on partner-driven commercialization for select assets, and European family-controlled origins (until IPO).
- Mundipharma: Family-owned global specialty pharma network with deep European roots and focus on pain, oncology, and specialty therapeutics. Comparable to Debiopharm in private family-controlled structure, specialty focus, and partnership-driven market access.
- Ligand Pharmaceuticals: US biopharma operating a royalty-based business model by in-licensing or acquiring assets and capturing milestone/royalty economics. Directly comparable to Debiopharm's out-licensing revenue model and platform-licensing approach (e.g., MultiLINK, AbYlink, Captisol-style technology licensing).
- Ferring Pharmaceuticals: Swiss-headquartered privately-held specialty biopharma focused on reproductive health, urology, and gastroenterology. Highly comparable to Debiopharm in geographic origin, family-controlled governance, therapeutic areas (including triptorelin co-marketing relationship), and mid-size employee footprint.
- Ipsen: French specialty biopharma with overlapping therapeutic focus in oncology, urology, and rare diseases. Ipsen is Debiopharm's long-term commercialization partner for Decapeptyl (triptorelin) and a direct comparable in size, specialty focus, and out-licensing-driven pipeline strategy.
Broad incumbents
- UCB: Belgian specialty biopharma with mid-size employee footprint and focus on neurology, immunology, and rare diseases. Comparable to Debiopharm in European specialty focus, mid-cap scale, and licensing-oriented pipeline expansion.
- Takeda: Japanese global pharma with significant specialty and oncology franchises, and a long-term commercialization partner of Debiopharm. Broader incumbent but operates in overlapping therapeutic areas (oncology, rare diseases, GI).
- Sanofi: French global pharma and historical licensee of Debiopharm's oxaliplatin (Eloxatin). Operates a much broader portfolio but a relevant comparator in oncology commercial scale, manufacturing footprint, and out-licensing relationships with mid-sized developers.
- Merck KGaA: German global science and technology company with a healthcare division focused on oncology, neurology, and fertility. Long-term Debiopharm commercialization partner; broader incumbent with comparable therapeutic areas and out-licensing posture.
Emerging players
- ADC Therapeutics: Clinical-stage biopharma focused exclusively on ADC development for hematological and solid tumors. Directly comparable to Debiopharm's ADC pipeline (Debio 1562M, Debio 0532, Debio 2512) and represents a relevant pipeline-level peer despite Debiopharm's broader scope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights8 records
Customer concentration
Debiopharm Group social profiles
Digital presenceDebiopharm Group compliance and trust
Trust signalCompliance3 records
Debiopharm Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Debiopharm Group leadership team
Management profileNumber of profiles
Profiles17 records
Debiopharm Group subsidiaries and ownership
Company hierarchySubsidiaries6 records
Debiopharm Group funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Debiopharm Group M&A and investment
M&A and investmentM&A1 record
Investments26 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Debiopharm Group
What does Debiopharm Group do?
Debiopharm in-licenses early-stage biologics and small-molecule compounds from universities and start-ups, develops them through preclinical and clinical stages using proprietary drug delivery platforms (PLGA-based DEBIO SPHERES sustained-release, MultiLINK ADC linkers, AbYlink antibody conjugation), and out-licenses to global pharmaceutical partners for commercialization. The group operates an FDA-inspected drug manufacturing facility in Martigny and a digital health investment fund backing AI/data start-ups.
Is Debiopharm Group a public or private company?
Debiopharm Group is a private company. It is classified as family owned and is currently operating.
When was Debiopharm Group founded?
Debiopharm Group was founded in 1979. It employs 251 to 500 people.
Where is Debiopharm Group based?
Debiopharm Group is headquartered in Lausanne, Switzerland, in the Europe region.
How does Debiopharm Group make money?
Three revenue lines are on record. Drug Development and Out-Licensing is the primary driver. The others are drug Manufacturing and digital Health Investment.
Who are Debiopharm Group's main competitors?
Direct peers on record are Recordati, Mundipharma, Ligand Pharmaceuticals, Ferring Pharmaceuticals and Ipsen. Broad incumbents are UCB, Takeda, Sanofi and Merck KGaA. ADC Therapeutics is listed as an emerging player.
Does Debiopharm Group have an API?
No public API is recorded for Debiopharm Group.
What industry is Debiopharm Group in?
Debiopharm Group's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2834.